Based in Belgium, Cellaïon is a startup. Brouky records 1 investor associated with the company.
Cellaïon is a Walloon biotechnology company developing therapies for severe liver diseases; its lead product HepaStem® is in advanced clinical development for Acute-on-Chronic Liver Failure (ACLF). The company’s pipeline also includes indications such as acute toxic hepatitis, acute decompensation and non-alcoholic steatohepatitis (NASH).
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.